NMN vs NR: Choosing the Right NAD+ Precursor for Anti-Aging
Neil Tuckwell·Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.··9 min read
NMN vs NR: Choosing the Right NAD+ Precursor for Anti-Aging
Every decade after your thirties, your cells are quietly running low on one of the most important molecules in biology. NAD+ (nicotinamide adenine dinucleotide) — the fuel that powers DNA repair, mitochondrial energy, and your body's biological clock — declines by roughly 50% between the ages of 40 and 60. Two compounds have emerged as the most promising ways to replenish it: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are real, both work, and both have now been tested in human clinical trials. The question is which one is right for you.
How NAD+ Works and Why It Declines
Think of NAD+ as the rechargeable battery inside every cell in your body. When the battery is full, your cells repair damaged DNA efficiently, burn fuel cleanly in the mitochondria, and regulate circadian rhythms with precision. When it runs low, everything slows down — and that slowdown looks a lot like what we call aging.
NAD+ powers three classes of enzymes that matter most for longevity: sirtuins (SIRT1 through SIRT7), which act as master regulators of metabolism and stress response; PARP enzymes, which patch breaks in your DNA; and CD38, a NADase that ironically rises with age and inflammation, consuming the very molecule your cells need most[9]. This creates a feedback loop: aging depletes NAD+, which impairs the systems designed to slow aging.
The good news is that both NMN and NR can refill the tank. They belong to what biochemists call the salvage pathway — a shortcut that bypasses the slow, inefficient de novo synthesis of NAD+ from tryptophan. NR is first converted to NMN by enzymes called NR kinases (NRK1/2); NMN is then adenylated by NMNAT enzymes to produce NAD+[9]. They are, in other words, two stops on the same road.
There is a twist worth knowing: a significant portion of orally ingested NMN may be dephosphorylated in the gut to NR before it ever reaches your cells — making the two blurrier inside your body than they appear on a label[9]. But blurry does not mean identical, because the research on each compound tells a distinct story.
What the NMN Evidence Shows
Frequently Asked Questions
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
NT
Neil Tuckwell
Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.
Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.
NMNNRNAD+longevity
Related Articles
anti-aging
Longevity Science
Fisetin and Quercetin as Senolytics: What Human Trial Data Reveals
What do human clinical trials actually show about fisetin and quercetin as senolytics? We break down the data, the numbers, and what they mean for you.
Neil Tuckwell·8 min read
If you are interested in functional benefits you can feel — better stamina, maintained mobility, improved sleep — the NMN literature is encouraging.
A multicenter, double-blind, placebo-controlled trial by Lin Yi et al. enrolled 80 healthy middle-aged adults aged 40 to 65 and gave them either placebo or 300, 600, or 900 mg of NMN per day for 60 days. All three doses significantly increased blood NAD+ concentrations versus placebo (p ≤ 0.001). More strikingly, the 300, 600, and 900 mg groups all showed statistically significant improvements in 6-minute walking distance (p < 0.01), with 600 mg appearing to offer an optimal balance of NAD+ elevation and functional benefit[2]. Biological age markers stabilized in the NMN groups while they continued to rise in the placebo group (p < 0.05).
A second trial by Morifuji et al. tested 250 mg per day in 60 older adults over 12 weeks. NMN maintained 4-meter walking speed and improved global sleep quality scores (PSQI) including daytime dysfunction[5]. A systematic review by Wen et al. pooling data from 437 participants across 10 RCTs confirmed the dose-dependent pattern: improvements in walking distance and aerobic capacity appeared reliably at 600 to 900 mg per day, with no serious adverse events across the entire sample[8].
One more angle: a 12-week trial by Katayoshi et al. at 250 mg per day found that NMN elevated serum nicotinamide levels and produced a trend toward reduced pulse wave velocity — a marker of arterial stiffness — though the result did not reach statistical significance in the small sample of 36 adults[4]. No adverse events were observed. The pattern that emerges across these trials is consistent: NMN is safe at 250 to 900 mg, reliably raises NAD+, and produces dose-dependent improvements in physical performance.
What the NR Evidence Shows
NR has its own compelling story — particularly if your interest is neurological health or you are looking for substantial, measurable NAD+ elevation.
The most dramatic NAD+ numbers in the research belong to NR. A 2025 randomized controlled trial by Wu et al. published in EClinicalMedicine (The Lancet) gave 58 long-COVID participants 2,000 mg of NR per day for 20 weeks. Within 5 to 10 weeks, NAD+ levels rose 2.6- to 3.1-fold[7]. Those are striking numbers. However, the trial failed to show significant between-group differences on its primary outcomes: cognitive function, fatigue, sleep quality, or mood all improved modestly in both groups, but NR did not outperform placebo on any primary or secondary endpoint. The study was small (only 18 participants completed the full 22-week protocol), and the disease state of long-COVID may have created ceiling effects. Exploratory within-group analyses did suggest improvements in executive function and fatigue — enough to keep this line of research alive.
For the brain, NR may have a distinct edge. A phase I trial by Brakedal et al. (the NADPARK study) gave 30 newly diagnosed Parkinson's disease patients 1,000 mg of NR per day for 30 days. Cerebral NAD+ levels rose significantly, mitochondrial and proteasomal gene expression was upregulated, and inflammatory cytokines dropped in both serum and cerebrospinal fluid[6]. The researchers nominated NR as a candidate neuroprotective therapy, pending validation in larger trials.
A systematic review and meta-analysis by Prokopidis et al. covering adults with mean ages between 60.9 and 83 found that neither NMN nor NR supplementation significantly preserved skeletal muscle mass (SMI meta-analysis MD = -0.42, 95% CI: -0.99 to 0.14, p=0.14) or gait speed (MD = -0.01, p=0.79)[1]. The one exception: NR showed improved walking distance specifically in peripheral artery disease patients. This nuance matters — both compounds may have population-specific windows where they work best.
Side Effects and Safety
Across all the human trials reviewed here, neither NMN nor NR produced serious adverse events. That consistency across multiple independent research groups is meaningful.
For NMN, the most comprehensive safety data comes from the systematic review by Wen et al.: 8.2% of participants reported minor adverse events such as nausea, headache, or transient flushing — a rate comparable to or lower than placebo groups in many supplement trials — and zero serious adverse events were recorded across 437 participants[8]. Individual trials by Lin Yi et al. and Katayoshi et al. similarly reported clean safety profiles at doses from 250 to 900 mg[2][4].
For NR, the long-COVID trial by Wu et al. saw some participant dropout, and the Brakedal et al. Parkinson's trial flagged the need for larger studies before drawing clinical conclusions[6][7]. One metabolic note deserves attention: a large meta-analysis by Zhong et al. pooling 14,750 participants across 40 articles found that NAD+ precursor supplementation as a class significantly elevated fasting glucose (SMD = 0.27, p = 0.0004)[3]. However, the authors noted that this effect was driven primarily by nicotinic acid data, not NMN or NR specifically — and dedicated NMN and NR trials have not replicated this glucose elevation[2][5]. Read broad meta-analyses carefully: not all NAD+ precursors are interchangeable.
Anyone with diabetes, metabolic syndrome, or taking anticoagulants should consult a healthcare provider before starting either compound, given NAD+'s roles in PARP-mediated DNA repair and the theoretical interactions with anticoagulant pathways[6][7]. High inter-individual variability in NAD+ response — with coefficients of variation ranging from 29.2% to 113.3% in some studies[4] — also means your experience may differ substantially from published averages.
How to Choose Between NMN and NR
No direct head-to-head randomized controlled trial comparing NMN and NR in the same human cohort currently exists[1]. What we have instead is a body of trials using different populations, doses, and durations — making confident ranking impossible. What it does allow is pattern recognition.
If physical performance and energy are your primary goals, the NMN evidence at 300 to 900 mg per day is more consistent across multiple independent trials. The dose-dependent walking distance improvements[2][8] and sleep quality benefits[5] give NMN a practical edge for active adults aged 40 to 65 who want functional markers to move in the right direction.
If neurological health and brain NAD+ are your focus, NR has a more developed research base. The NADPARK study's cerebral NAD+ findings and inflammatory cytokine reductions in a neurological disease context are not replicated in the NMN literature to the same degree[6].
If you want the highest measured NAD+ elevation, NR at 2,000 mg per day produced the most dramatic increases (2.6 to 3.1-fold) in the literature[7] — though that elevation did not translate into clinical benefit in the long-COVID population studied.
If dose efficiency matters, NMN at 250 mg produced meaningful results in older adults[5], suggesting lower doses can still drive NAD+ elevation and functional benefit.
The emerging view among researchers is that both precursors likely act through overlapping mechanisms — and that personalized NAD+ monitoring may eventually become the standard approach[4]. Until then, the choice between NMN and NR is less about one being superior and more about matching the evidence profile to your specific situation.
If you are a healthy middle-aged adult focused on physical performance and sleep, the current evidence leans NMN. If you are exploring NAD+ for neuroprotective applications, NR has more research in that direction. And if you are simply starting out, either compound at a moderate dose appears safe and capable of raising NAD+ — which is the foundation everything else builds on.
Frequently Asked Questions
Q. Is NMN better than NR for anti-aging?
Neither has been proven superior in a direct head-to-head human trial[1]. NMN currently has stronger evidence for physical performance benefits (walking distance, sleep quality) in healthy middle-aged and older adults[2][5][8]. NR has more evidence in neurological contexts, including a study showing brain NAD+ elevation and reduced inflammation in Parkinson's disease patients[6]. Which compound suits you depends on your health goals.
Q. How much NMN or NR should I take?
For NMN, human trials showing functional benefits have used doses ranging from 250 mg to 900 mg per day, with 300 to 600 mg appearing effective for NAD+ elevation and physical performance[2][5]. For NR, studies have used 1,000 to 2,000 mg per day to achieve significant NAD+ increases[6][7]. Given high inter-individual variability in NAD+ response[4], consulting a healthcare provider before establishing a dose is advisable.
Q. Are NMN and NR safe to take long-term?
Human trials ranging from 30 days to 24 weeks have not identified serious adverse events for either compound[2][4][5][6][7][8]. Minor effects such as nausea or flushing occurred in roughly 8.2% of participants across NMN studies[8]. One meta-analysis flagged fasting glucose elevation as a class effect for NAD+ precursors broadly, but this appeared driven by nicotinic acid rather than NMN or NR specifically[3]. Long-term safety data beyond six months in humans remains limited.
Q. Can I take NMN and NR together?
No clinical trial has tested the combination in humans. Since a portion of ingested NMN may convert to NR in the gut before absorption[9], combining both compounds could mean overlapping pathways rather than additive effects. There is no established evidence that taking both produces greater benefit than taking either alone at an optimized dose.
Q. Do NMN and NR really raise NAD+ levels?
Yes — this is one of the most consistently replicated findings across both compounds. NMN at doses from 250 to 900 mg per day significantly elevated blood NAD+ concentrations in multiple independent RCTs[2][4][5]. NR at 2,000 mg per day raised blood NAD+ by 2.6 to 3.1-fold within 5 to 10 weeks[7], and 1,000 mg per day significantly increased cerebral NAD+ in a Parkinson's disease trial[6]. Raising NAD+ is the established first step; translating that into clinical benefit is the more complex and ongoing scientific question.
References
[1] Prokopidis K et al., "The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis," Journal of Cachexia, Sarcopenia and Muscle, 2025. DOI: 10.1002/jcsm.13799
[2] Lin Yi et al., "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial," GeroScience, 2023. DOI: 10.1007/s11357-022-00705-1
[3] Zhong O et al., "Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis," Nutrition and Metabolism (London), 2022. DOI: 10.1186/s12986-022-00653-9
[4] Katayoshi T et al., "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial," Scientific Reports, 2023. DOI: 10.1038/s41598-023-29787-3
[5] Morifuji M et al., "Ingestion of beta-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study," GeroScience, 2024. DOI: 10.1007/s11357-024-01204-1
[6] Brakedal B et al., "The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease," Cell Metabolism, 2022. DOI: 10.1016/j.cmet.2022.02.001
[7] Wu H et al., "Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial," EClinicalMedicine (The Lancet), 2025. DOI: 10.1016/j.eclinm.2025.103633
[8] Wen M et al., "Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials," Cureus, 2024. DOI: 10.7759/cureus.65961
[9] Alegre GFS and Pastore GM, "NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health," Current Nutrition Reports, 2023. DOI: 10.1007/s13668-023-00475-y
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
